Q8IC32 AF NFT

Leucine-rich repeat and coiled-coil domain-containing protein PF3D7_0703800

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeidwuly5h2hmpo5t4gtqkcubm3vxwnsxojr3puzsj7cczagujvbb4a/metadata.json
IPFS of structure file: 
bafybeia34kjp7lz4zh3zb37fczissojxk5a7fkhdpzhplsvjzocep65joq/AF-Q8IC32-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x37932119Cdc7B361976632F22197638CC2F2FDd5
First NFT owner address (bech32): 
genesis1x7fjzxwdc7ekr9mxxtezr9mr3np09lw40u7hhw
Current NFT ID #521007 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1_w

NFT id:
521007
Accession (UniProt):
Q8IC32
Name::
Leucine-rich repeat and coiled-coil domain-containing protein PF3D7_0703800
Experimental Method:
Predicted structure
Sequence source:
PLASMODIUM FALCIPARUM (ISOLATE 3D7)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q8IC32 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q8IC32|Y7014_PLAF7 Leucine-rich repeat and coiled-coil domain-containing protein PF3D7_0703800 OS=Plasmodium falciparum (isolate 3D7) OX=36329 GN=PF07_0014 PE=1 SV=1 MAIKKKKKETKSKDNNNDNLRNEKKSTNLENGKYDKKKVEIYEHGIGGITQNKNDNNKENAYDDDIYHDKSEHINVKYLNEKDYEIEKVSKRIYEENSKIKKISLHHKILKEELETKQLIEQNDKKKKNSLDYYKKVIIKLKNNINNMEEYTNNITNDINVLKAHIDDERNERIIYNNNMKILINEYNSLKKNIQDLNMQEKEQHKFNTKLKEELKELYKEKENMEKKHREDFKKLQQKIKEQKILSYENKINDLTKEKDKNKMENGEANKYEDKHNNNNIHNNNNIHNDNNICNDNNICNDNTIHNDNNICNDNNICNDNNICNDNNICNDNNIRNNNIISSNNKIHEKDNMINILNYYEDEKKKQLQNKIVMLKKLCLRILFINEYQIYNIKKLQENINNMNNAINSINLISYKKGDFDHIIINLNVSKEKNYSLISRINLLNYETNVLKQLIKKMKEKFKHLNLQNDEIINLKYDISNNMNEKMKHIKTSLLTNQETCNLKKKCFDDCLLYLKQLYTFIKNYENNNDKLNIKSQIINKDKNLHFNYIHKYNEDILVDENYINDFLIYIEKYIYSLNFYLPTQNFNYKKYLLHNGSIHNITLDTHASSKEYLQKEDSSEFNQHGHNLLRDSLNLNEQQENKDHLQHEEHTHEEEPKDANGDMVNIEDANGDMVNIEDANGDMVNIKDANGDMVNIKDTRGDIENIEDKSGDMENMKEPNGDMENMKEPNDDIQILKEPNDDIQILKEPNDDIQILKEPNDDIQILKEPNDDIQILKEPNDDIQILKEPNDDIQILKDPNDDIQILKEPNDDISTINNLTTHLSNENNLMTDLPKVDHKIKDEIQSEHILESTNISDDNINKENSLEIPLNYDHTQENILKNKNNMEDQNNLLEQNIMTDQLQNHKECEEFKPHDNKEKNNIINDDTKNLISDDTKNIISDDTKNIISNDTKKILSDDTKNIISDDTKNIINDDTKNISNDDIKNISNDDIKNIGNDNNKPYNEDHNIVTINDEKANYILNHFNSRNIEYDKLKEEIPNELLNIKYDSSKKSTISTN